|
| ||
|
|
||
Choroidal Neovascularization Secondary (choroidal + neovascularization_secondary)
Selected AbstractsEXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degenerationACTA OPHTHALMOLOGICA, Issue 3 2010Yasuo Tano Abstract. Purpose:, To evaluate the efficacy and safety of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Japanese patients. Methods:, This open-label, multicentre, Phase I/II study enroled patients into Group A (single injection of ranibizumab nonrandomized doses of 0.3 or 0.5 mg followed by 11 monthly injections of the same dose) and Group B (12 monthly injections of ranibizumab randomized to 0.3 or 0.5 mg). The primary efficacy endpoint was the mean change from baseline in best-corrected visual acuity (BCVA) score at Month 6. Safety was evaluated in all patients who received ranibizumab. Results:, Of 88 patients enroled, 12 entered Group A (six per dose) and 76 entered Group B (0.3 mg: n = 35; 0.5 mg: n = 41). Mean change from baseline in BCVA was significantly increased for both doses (Group B) at Month 6 (0.3 mg: +8.1 letters, p = 0.0006; 0.5 mg: +9.0 letters, p < 0.0001) and Month 12 (0.3 mg: +9.5 letters, p = 0.0001; 0.5 mg: +10.5 letters, p < 0.0001). At Month 12, one patient (0.3 mg) and 0 patients (0.5 mg) lost ,15 letters, while 37.1% (0.3 mg) and 31.7% (0.5 mg) of patients gained ,15 letters. Ocular serious adverse events (SAEs) of the study eye were reported in 1 and 2 patients in the 0.3- and 0.5-mg groups, respectively. Nonocular SAEs were experienced by 2 and 5 patients in the 0.3- and 0.5-mg groups, respectively. No cases of endophthalmitis were reported. Conclusion:, Ranibizumab was effective and well tolerated in Japanese patients with subfoveal CNV secondary to AMD. [source] Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathyACTA OPHTHALMOLOGICA, Issue 2 2010Nikolaos Mavrakanas No abstract is available for this article. [source] Intravitreal pegabtanib sodium in choroidal neovascularization secondary to angioid streaksACTA OPHTHALMOLOGICA, Issue 5 2009Ines Molina Guilabert No abstract is available for this article. [source] Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteomaACTA OPHTHALMOLOGICA, Issue 1 2009Won Kyung Song No abstract is available for this article. [source] Acute retinal necrosis post intravitreal injection of triamcinolone acetonideCLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 4 2006Tze'Yo Toh MB BS (Hons) Abstract Although few data exist on the complication of intravitreal injection of triamcinolone acetonide (IVTA) in human eyes, it is generally thought to be well-tolerated. The commonest reported adverse events are raised intraocular pressure and progression of cataract. Acute retinal necrosis, as far as the authors are aware, has not been reported to be associated with IVTA in the literature before. The authors hereby report such a case in a patient who has IVTA as an adjunct to photodynamic therapy of choroidal neovascularization secondary to age-related macular degeneration. [source] | ||||||||||